Amgen, J&J settle sales-discount lawsuit

Amgen agreed to pay $200 million to settle an antitrust lawsuit by Johnson & Johnson's Ortho Biotech unit, putting to rest 2½ years of legal wrangling over Amgen's sales of its oncology products Aranesp, Neupogen, and Neulasta. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.